Publication | Closed Access

Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

Hematological MalignancyCell TherapyCellular TherapiesImmunologyHematologyConsolidation TherapyStem Cell TherapiesPhase 2ImmunotherapyMedicineCell BiologyNatural Killer CellsMyeloid Neoplasia